Brief: Astria, Kaken Ink Deal to Develop Navenibart for HAE in Japan

Astria Therapeutics

06/08/2025 13:26

Aug 6 (Reuters) - Astria Therapeutics Inc ATXS.O:

ASTRIA THERAPEUTICS ENTERS INTO LICENSING AGREEMENT WITH KAKEN PHARMACEUTICAL TO DEVELOP AND COMMERCIALIZE NAVENIBART FOR HAE IN JAPAN

ASTRIA THERAPEUTICS INC - UP TO $32 MILLION IN PAYMENTS PLUS ROYALTIES

ASTRIA THERAPEUTICS INC - EXPECTS CASH RUNWAY TO SUPPORT OPERATING PLAN INTO 2028

Source text: ID:nBw97ZYSBa

Further company coverage: ATXS.O

 ((Reuters.Briefs@thomsonreuters.com;))